- Home
- BROS vs ABVX Comparison
BROS vs ABVX Comparison
Compare BROS & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BROS
- ABVX
- Stock Information
- Founded
- BROS 1992
- ABVX 2013
- Country
- BROS United States
- ABVX France
- Employees
- BROS N/A
- ABVX N/A
- Industry
- BROS Restaurants
- ABVX
- Sector
- BROS Consumer Discretionary
- ABVX
- Exchange
- BROS Nasdaq
- ABVX Nasdaq
- Market Cap
- BROS 7.4B
- ABVX 6.7B
- IPO Year
- BROS 2021
- ABVX N/A
- Fundamental
- Price
- BROS $55.54
- ABVX $102.42
- Analyst Decision
- BROS Strong Buy
- ABVX Strong Buy
- Analyst Count
- BROS 18
- ABVX 10
- Target Price
- BROS $77.39
- ABVX $103.80
- AVG Volume (30 Days)
- BROS 4.1M
- ABVX 1.1M
- Earning Date
- BROS 11-05-2025
- ABVX 08-11-2025
- Dividend Yield
- BROS N/A
- ABVX N/A
- EPS Growth
- BROS 75.89
- ABVX N/A
- EPS
- BROS 0.48
- ABVX N/A
- Revenue
- BROS $1,451,963,000.00
- ABVX $7,073,400.00
- Revenue This Year
- BROS $27.79
- ABVX $4.44
- Revenue Next Year
- BROS $25.11
- ABVX N/A
- P/E Ratio
- BROS $115.89
- ABVX N/A
- Revenue Growth
- BROS 29.80
- ABVX N/A
- 52 Week Low
- BROS $32.68
- ABVX $4.77
- 52 Week High
- BROS $86.88
- ABVX $108.00
- Technical
- Relative Strength Index (RSI)
- BROS 47.79
- ABVX 72.42
- Support Level
- BROS $54.03
- ABVX $90.85
- Resistance Level
- BROS $60.22
- ABVX $94.26
- Average True Range (ATR)
- BROS 2.10
- ABVX 3.99
- MACD
- BROS 0.49
- ABVX 0.55
- Stochastic Oscillator
- BROS 53.15
- ABVX 72.65
About BROS Dutch Bros Inc.
Dutch Bros Inc is an operator and franchisor of drive-thru coffee shops that are focused on serving hand-crafted beverages. The company's hand-crafted beverage-focused lineup features hot and cold espresso-based beverages, cold brew coffee products, proprietary energy drinks, tea, lemonade, smoothies and other beverages. The company has two reportable operating segments Company-operated shops and Franchising. It derives maximum revenue from Company operated shops.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.